A conversation about the realities healthcare supply chain leaders see every day: where margin is lost, how operating constraints shape choices, and why the clearest opportunities often sit beneath the surface.

The discussion continues with a closer look at the decisions, trade-offs, and recurring patterns that determine financial performance across the healthcare supply chain.

Healthcare organizations hold enormous value in their data, but fragmented systems and familiar ways of looking at information can keep that value hidden. This conversation examines the blind spots.

Changing outcomes begins with changing how teams recognize problems. The episode explores what it takes to build new analytical habits inside a complex, legacy healthcare environment.

Better negotiations start before the meeting. This conversation looks at how granular, trusted data changes the balance of information and gives healthcare teams leverage with vendors.

A practical view of the themes shaping healthcare now — separating durable operating realities from noise and examining what leaders should pay attention to next.

How health systems can respond as OBBBA reshapes financial assumptions, operating priorities, and the decisions leaders need to make.

A closer look at how more ambitious savings targets change leadership priorities and the way healthcare organizations evaluate opportunity.

Why OBBBA calls for more than incremental change — and what healthcare leaders may need to rethink about the rules of the game.

The practical challenge of leading transformation when urgency, institutional constraints, and competing priorities all collide.

How supply chain credibility becomes a strategic asset when financial pressure brings operating decisions into the boardroom.

Why control of trusted, granular data determines who can frame the question, challenge assumptions, and shape the final decision.

A look at the people, evidence, and institutional forces that influence healthcare’s largest investment decisions.

Who gets to define technology priorities in healthcare — and how those choices shape the system’s future capabilities.

Examining whether major industry investments translate into better patient outcomes — and how that connection should be measured.

What makes a technology investment rational when capital is constrained, evidence is incomplete, and the cost of getting it wrong is high?